Abstract 2676
Background
Oncology nurses are responsible to provide their patients with the evidence-based care. Clinical guidelines or recommendations can be developed by scientific associations as a guide for performing evidence-based practice. These guidelines are often taken into consideration for the assessment of professional responsibility, as well as to guide the practice. The Italian Institute of Health identified the Italian Association of Cancer Nurses (AIIAO) among the scientific societies authorised to produce, adapt and implement guidelines. However, it is important to identify which areas of oncology nursing warrant an action to facilitate AIIAO in setting the agenda. A specific prerequisite for developing high-quality guidelines is incorporating nurses’ views into priority-setting. The aim of this study is to use a bottom-up approach to empirically investigate which areas of oncology nursing require higher priority in the definition of evidence-based recommendations.
Methods
This is a multi-phase study including a cross-sectional national survey. In order to develop the tool for the survey, a systematic search of the literature, a focus group, and content and face validity evaluation will be conducted.
Results
Seven areas were identified by the literature review to develop the survey: (a) fatigue; (b) pain; (c) sleep disorders; (d) secondary symptoms; (e) cognitive impairment resulting from cancer and its treatment; (f) chemotherapy-induced peripheral neuropathy; and (g) psychological distress. This research is still ongoing. A panel of researchers are operationalising the identified areas in the items for the national survey. Cancer nurses will be asked to rate the priority of each area for the implementation, adaptation and development of AIIAO clinical guidelines.
Conclusions
The results of this survey might raise awareness about oncology nurses’ opinions on which areas of clinical practice warrant an action. This will facilitate the associations and affiliated working groups in developing evidence-based recommendations. Moreover, a bottom-up mapping of the nurses’ priorities will inform the planning of AIIAO strategic activities targeted to strengthen cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Italian Association of Cancer Nurses (AIIAO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract